CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Status:
Terminated
Trial end date:
2018-02-12
Target enrollment:
Participant gender:
Summary
Background:
The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get
when abnormal cells begin to grow in this gland. Researchers believe a new drug called
CUDC-907 may be able to help people with thyroid cancer that has spread or has gotten worse.
Objective:
To see if CUDC-907 will shrink tumors in people with advanced thyroid cancer.
Eligibility:
People at least 18 years old who have been diagnosed with locally advanced and metastatic
thyroid cancer.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Electrocardiogram (ECG) heart test.
Review of their symptoms and how they perform normal activities
A scan will be performed. Some will have a computed tomographic scan (CT) that takes pictures
of the body using a small amount of radiation. Some will have magnetic resonance imaging
(MRI) that uses a magnetic field to take pictures.
Bone scan (some participants)
Fludeoxyglucose (FDG) positron emission tomography (PET) scan to produce a tumor image.
A sample of their tumor from a previous surgery. They may have a biopsy of their tumor if a
tumor sample is not available from a previous surgery.
Participants will be given CUDC-907 in tablet form. They will take it by mouth once a day for
5 days, then take 2 days off, each week.
While taking the study drug, participants will have study visits that repeat the screening
tests.
After they stop treatment, participants will have 3 follow-up visits over a year. They will
repeat some tests. Then participants will be contacted by phone or e-mail every 6 months....